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ABSTRACT 
Investigator: Dr Pushpa Masiwal, Prof. Dr K S Chenthil. 
Background: The presence of cardiac autonomic neuropathy (CAN) in patients 
with type 2 diabetes mellitus (T2DM) is associated with chronic micro vascular 
complications and increased mortality. 
Objective: To assess the prevalence of CAN in T2DM and to investigate any 
possible association between CAN and micro vascular complications. 
Method: In this observational study, patients underwent laboratory 
investigations, biothesiometry, fundus examination, and CAN assessment by 
CANS analyser. 
Results: The prevalence of CAN dysfunction was found to be 80.39% 
according to our study. CAN was found to be significantly associated with age 
of patients, diabetic neuropathy and diabetic retinopathy. 
Conclusion: CANS dysfunction appears much before patients manifest signs 
and symptoms of this condition and it is correlated with other micro vascular 
complications. 
Keywords: Type 2 Diabetes Mellitus, Cardiac  Autonomic Neuropathy, Micro 
vascular Complications. 
 
 
                                                                                                             1 
 
 
 
INTRODUCTION 
One of the most overlooked and serious complications of the most 
common and dreaded non communicable disease Diabetes Mellitus is 
cardiac autonomic neuropathy. 
Information regarding the frequency of cardiac autonomic 
neuropathy in diabetic population is limited. It has poor prognosis and at 
times presents with orthostasis, exercise intolerance, postural 
hypotension, enhanced intra-operative and peri-operative cardiovascular 
instability and increased incidence of silent myocardial infarction and 
ischemia and sudden death. 
This could be due to functional abnormality or structural damage to 
various components of ANS. Systemic hypertension, distal symmetrical 
peripheral neuropathy, retinopathy and persistent poor glycemic status are 
in general major risk factors in the development of cardiac autonomic 
neuropathy in both Type 1and Type 2 Diabetes Mellitus. 
This study aims to assess the prevalence of CAN among the 
patients of T2DM of varying duration and correlate any possible 
influences of age, duration of diabetes, hypertension, coexistent 
peripheral neuropathy, nephropathy and/or retinopathy on occurrence of 
cardiac autonomic neuropathy. 
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AIMS AND OBJECTIVES 
To study the prevalence of CAN in T2DM in south Indian 
population. 
To correlate the prevalence of cardiac autonomic neuropathy in 
Type 2 Diabetes Mellitus with duration of disease, severity and other 
microvascular complication. 
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REVIEW OF LITERATURE 
Diabetes Mellitus is a group of metabolic disorders with 
hyperglycaemia as a common phenotype. It is a chronic and complex 
illness which requires regular medical care beyond glycaemic control. 
Diabetes has been classified into different types according to the 
etiopathogenesis.  
The latest classification as given in ADA2014 publication is 
included here. 
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DIAGNOSIS OF DIABETES 
As per ADA 2014 guidelines 
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TYPE 2 DM NATURAL HISTORY 
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TYPE2 DM  NATURAL HISTORY 
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PATHOGENESIS 
It is complex due to varying combination of insulin resistance and 
relative insulin deficiency. 
INSULIN RESISTANCE 
T2DM is often associated with visceral obesity, dyslipidaemia and 
hypertension and is called insulin resistance syndrome 
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Central obesity is the most important factor in insulin resistance. 
The above mentioned cluster of conditions predispose to cardiovascular 
disease. What is the main cause of insulin resistance is still unclear. The 
metabolically active central adipose tissue (intra-abdominal) releases free 
fatty acids which in the peripheral tissue compete with glucose for 
oxidation which in turn induces insulin resistance4.  
Hormones like adipokines, which are released form adipose tissue 
act on specific receptors to influence sensitivity in various tissues. 
Another important determinant of insulin sensitivity is physical activity. 
Physical inactivity causes down regulation of insulin sensitive 
kinases which cause accumulation of free fatty acids within skeletal 
muscles. Therefore sedentary people with same BMI are more insulin 
resistant than active people3. 
Fat deposition in the liver is often associated with central obesity 
and is exacerbated by insulin resistance. Most people with T2DM have 
fatty infiltration of liver which may improve with effective treatment of 
diabetes and dyslipidaemia.  
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RELATIVE INSULIN DEFICIENCY (Pancreatic Beta Cell Failure): 
At the time diabetes is diagnosed in an individual, about 50% of 
beta cell mass of pancreas is already lost. The most important 
pathological change of T2DM is deposition of amyloid around pancreatic 
beta cells. Added on to this, elevated blood sugar levels and free fatty 
acids exert a toxic effect on pancreatic beta cells further impairing insulin 
secretion. The alpha cell mass remains unchanged leading to increased 
glucagon secretion which contributes to hypoglycaemia.  
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GENETIC PREDISPOSITION 
Various studies have shown the concordance rates for T2DM 
among monozygotic twins is around 100%. Apart from genetic 
involvement development of diabetes is influenced by strong 
environmental factors.  
Over 20 genes have been identified to be associated with T2DM. 
The genetic variation in TCF7L2 exerts a large effect in development of 
T2DM. 10% of the population having 2 copies of this high risk variant 
have 2 fold increased risk of development of T2DM.2  
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ENVIRONMENTAL AND OTHER RISK FACTORS 
Diet and Obesity: 
Over eating combined with obesity and under activity are 
associated with increased incidence of T2DM. There is a tenfold increase 
in T2DM in people with Body Mass Index more than 30݇݃/݉ଶ. Obesity 
is a diabetogenic factor in genetically predisposed individuals. Foods rich 
in carbohydrates increase demand for insulin secretion, and fatty foods 
increase insulin resistance 
 
Age   
T2DM is common in middle age and elderly people. Recent studies 
in India have shown increased incidence of T2DM in adolescent age 
group, this is due to poor dietary habits, sedentary lifestyle and obesity. 
Pregnancy  
Pregnancy by itself is an insulin resistant state where the pancreatic 
beta cells are not able to meet the increased insulin demands in 
pregnancy. This is due to the placental hormones which affects the 
glucose tolerance in pregnancy. 
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COMPLICATIONS OF DIABETES MELLITUS 
MICROVASCULAR COMPLICATIONS 
Diabetic Retinopathy  
It is the most common micro-vascular complications leading to 
blindness in diabetes. Early diagnosis by annual fundus examination is 
mandatory in all diabetic individuals.  
Hypoglycaemia per se increases retinal blood flow and vasoactive 
substances production increases. There is endothelial cell proliferation 
which causes closure of capillaries. Long term hypoxia increases the 
production of vascular endothelial growth factor (VEGF) leading to 
endothelial cell proliferation and increased vascular permeability.30 
Modifiable Risk Factors  
 Hyperglycaemia 
 Hypertension 
 Dyslipidaemia 
 Smoking 
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Non Modifiable Risk Factors 
 Duration of diabetes 
 Age 
 Genetic predisposition 
 Ethnicity 
Pathophysiological Events in Diabetic Retinopathy 
 Basement membrane thickening 
 Pericyte loss 
 Increased capillary permeability 
 Microaneurysms 
 Smooth muscle death 
 Capillary weakening 
 Reduced retinal blood flow 
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CLINICAL FEATURES OF DIABETIC RETINOPATHY 
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SEVERE  NON PROLIFERATIVE DIABETIC RETINOPATHY 
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FUNDUS FLOURESEIN ANGIOGRAPHY 
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Investigative Techniques for Diabetic Retinopathy: 
 Digital colour retinal photography 
 Fundus fluorescein angiography 
 Optical coherence tomography 
 Ultrasound B scan examination 
 Perimetry 
Screening for Diabetic Retinopathy  
Universal screening for diabetic retinopathy is mandatory for all 
diabetic individuals. Fundus examination using ophthalmoscope is the 
screening procedure in clinical setup. Incidence of diabetic retinopathy 
increases with increasing duration of diabetes, for T2DM screening starts 
at the time of diagnosis whereas for T1DM it usually starts after 5 years 
of diagnosis. 
Treatment of Diabetic Retinopathy 
 Laser photocoagulation 
 Vascular endothelial growth factor inhibitors like Bevacizumab 
and Ranibizumab 
 Vitrectomy 
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POST – PAN RETINAL PHOTO COAGULATION 
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DIABETIC NEPHROPATHY 
Around 40 % of diabetic individuals are affected by Diabetic 
Nephropathy. It is the most frequent reason for kidney disease in patient 
undergoing renal replacement therapy. It is characterised by slowly 
increasing urinary albumen excretion over the years accompanied by 
gradually rising blood pressure and a fall in GFR.24  
Once diabetic nephropathy sets in, there is an increased risk in the 
diabetic patient to develop other micro vascular as well as macro vascular 
complications of diabetes. Leading cause of death in Diabetic 
nephropathy is from cardiovascular diseases. Clinically Diabetic 
nephropathy occurs in two stages, viz: microalbuminuria and 
macroalbuminuria. 
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RISK FACTORS OF DIABETIC NEPHROPATHY 
Modifiable  
 Hyperglycemia        
 High Blood Pressure                
 Dyslipidemia  
 Smoking  
 Increased protein intake 
Non- Modifiable        
 Duration of Diabetes 
 Genetic Predispotion 
PATHOGENESIS OF DIABETIC NEPHROPATHY  
Classic Glomerulosclerosis is characterized by 
 Glomerular basement membrane thicknening 
 Diffuse  mesangial sclerosis 
 Hyalinosis 
 Microaneurysms 
 Hyaline arteriosclerosis 
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SCREENING TEST FOR DIABETIC NEPHROPATHY  
 Spot albumin – creatinine ratio 
 24 hrs urinary protein and creatinine and creatine clearance 
 Urinary protein in timed (4 hrs )  or overnight collection  
 
 Since there is day –to-day variability in albumin excreation atleast 
2 of 3 collections done in 3-6 month period must be elevated. 
 Screening for Diabetic Nephropathy in T1DM begins 5 yrs after 
diagnosis but poor glycemic control in the first 1 yr of diagnosis 
screening starts after 1 yr and yearly thereafter.In T2DM screening starts 
at time of diagnosis and yearly follow up is necessary. 
TREATMENT OF DIABETIC NEPHROPATHY 
 Strict glycemic control 
 Blood pressure control 
 Avoiding nephrotoxic drugs 
 Dialysis 
 Renal transplantation 
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DIABETIC NEUROPATHY 
Diabetic neuropathy is fairly common complication in diabetes.   
Neuropathy clinically manifests as numbness of feet which results in 
ulceration and infection, neuropathic pain which can be severe and 
disabling, and autonomic neuropathy which can involve several systems. 
Prevalence rates of diabetic polyneuropathy is approximately 30% among 
diabetic population.  
The prevalence of neuropathy is associated with increasing age, 
poor glycaemic status and longer duration of the disease.1 Neuropathy is 
often associated other microvascular complications. Increasing height and 
cardiovascular risk factors (cigarette smoking, hypertension, 
hyperlipidaemia) also associated with increased prevalence of 
neuropathy. The type of diabetes does not appear to influence its 
prevalence.  
The onset and triggers for diabetic neuropathy are not very clear. 
They are the cause of pain, distress, suffering and poor quality of life. If 
not taken care of in the early stages, this neuropathy can lead to foot 
ulceration. Charcot’s neuroarthropathy may develop and patient with 
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improper care and control can undergo amputations which is actually a 
potentially preventable condition.6 
 
DEFINITION  
The simplest definition of Diabetic Neuropathy is: "the presence of 
symptoms and/or signs of peripheral nerve dysfunction in people with 
diabetes after exclusion of other causes" (Boulton AJM, Jervell J: 1997).  
PATHOGENESIS  
The DCCT results have demonstrated a significant decrease in 
development and progression of symptomatic neuropathy (64%). 
Asymptomatic neuropathy which is detected by nerve conduction studies 
(44%), and also autonomic dysfunction which is about 53% in T1DM 
individuals with optimal glycemic control.  
Similarly symptomatic and asymptomatic neuropathy develops and 
progresses gradually over years and is related to both hyperglycemia and 
hypoinsulinemia in type 2 diabetic patients.  
Hyperglycaemia sets in a complex chain of events which include 
polyol pathway activation, depletion of myoinositol, reduction in PKC 
activity and a decrease in activity of nerve Na+ , K+ -ATPase. These 
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changes are implicated in the development of a reduction in nerve 
conduction velocity. 
 
The characteristic feature of distal symmetrical neuropathy is distal 
axonal loss, which is associated with an exclusive ‘dying back’ 
phenomenon.  Myelinated fibre density is reduced. It is difficult to assess 
small unmyelinated fibres which contribute upto 80% of nerve fibres   
Diabetic peripheral nerve injury- possible hypothesis: 
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PATHOGENESIS OF DIABETIC NEUROPATHY 
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POLYOL PATHWAY HYPERACTIVITY 
Glucose is normally converted by the action of enzyme hexokinase 
into glucose -6-phosphate. When there is hyperglycaemia this excess 
glucose is first reduced to sorbitol by the action of another enzyme aldose 
reductase. The sorbitol so formed, then changes to fructose under the 
influence of sorbitol dehydrogenase.  
The elevated sorbitol levels in diabetic nerves is associated with 
depletion of myoinositol and also a decrease in Na+ -K+ -ATPase which 
is necessary for exchange of intracellular as well as extracellular sodium 
and there by nerve membrane potential. ARI’s help in improvement in 
nerve conduction velocity.    
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THE POLYOL PATHWAY 
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NON-ENZYMATIC GLYCATION 
Non-enzymatic glycosylation of proteins is a feature of diabetes 
and is a initiating factor for nerve demyelination associated with 
interference of axonal transport. AGE  absorb NO leads to reduction in 
blood flow to the nerves.  Aminoguanidine, an avid inhibitor of AGE 
formation improves deficits in nerve conduction.  
OXIDATIVE STRESS 
Increased free radical generation due to non-enzymatic glycation 
and increased activity of polyol pathway leads to NADH depletion.  
Hence the nerve function is impaired by oxidative stress compounded by 
its toxic effects and by decreased NO and reduced blood supply to the 
nerves 
NEUROTROPHIC FACTORS 
Experimental diabetes shows reduction in growth factor eg: I,II and 
neurotrophin family. Treatment with nerve growth factor improves 
sensory neuropathy caused by dysfunction of small fibre. 
 
 
 
                                                                                                             29 
 
 
 
 
ACTIVATION OF PROTEIN KINASE C 
Increased activity causes increase in synthesis of  diacylglycerol 
(DAG) which leads to abnormalities in the vascular function. Treatment 
with PKC inhibitor corrects deficits in the retinal perfusion and prevents 
early glomerular hyperfiltration and increases in urinary albumin 
excretion among the diabetic rats and it has also shown to improve nerve 
conduction velocity, improve perfusion deficits and may even protect 
endothelial relaxation.   
MICROVASCULAR FACTORS 
Thickening of basement membrane of endoneural capillaries, 
pericytes degeneration, hyperplasia, and the swelling of the endothelial 
cells and at times blood vessel blockage are some common microvascular 
changes that can be seen in nerves.   Impairment of blood flow to nerves 
can cause a reduction in endoneural oxygenation. 
To summarize, a lot of metabolic abnormalities are brought about 
by the diabetic state as mentioned above which have a negative impact on 
nerve perfusion but the vascular endothelium is the major target.   
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Activation of the PKC system, oxidation stress and non-enzymatic 
glycation and decreased neurotrophic factors cause reduction in nerve 
NO.   
Endoneural capillary occlusion and the haemorrhagic abnormalities 
which are associated with diabetes can further worsen the blood flow to 
the nerves causing hypoxia and thus lead to structural and also functional 
abnormalities in the nerves. 
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CLASSIFICATION OF DIABETIC NEUROPATHY 
Neuropathy is classified according to clinical presentation. Various 
classifications are available but the commonly used one is as follows 
1.Chronic, progressive distal symmetric polyneuropathy  
 Mixed sensorimotor  
 Predominantly sensory  
 Predominantly autonomic  
2. Acute axonal polyneuropathy  
 acute, painful, weight loss, poor control (cachexic)  
 acute, painful, weight gain, good control (insulin neuritis)  
3. Proximal motor neuropathy (Amyotrophy)  
4. Mononeuropathies 
 mononeuropathy multiplex  
 cranial  
 truncal 
5. Entrapment neuropathies 
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CHRONIC SENSORY MOTOR NEUROPATHY (CHRONIC 
DISTAL SYMMETRICAL NEUROPATHY) 
It is the most common neuropathic syndrome which often affect 
more than 80% of patients with neuropathic symptoms. It’s a diffuse and 
symmetrical disorder which usually affects the lower limbs in stocking 
fashion, involvement of the hands in a glove pattern being rare. The 
pattern of sensory loss is length-related.  
Most patients with chronic sensory motor neuropathy will have an 
autonomic component which is often sub-clinical and detected only by 
formal testing.  As the disease advances, it becomes a sensory motor 
neuropathy, although significant motor involvement is uncommon early 
in the natural history of the disease.  The onset is gradual and progresses 
with increasing duration of diabetes.   
The incidence of chronic sensory motor neuropathy appears to be 
related to poor glycaemic control. While autonomic dysfunction is 
common, symptoms of autonomic neuropathy are rare.  Abnormal 
cardiovascular tests have been reported in 16-40% of diabetic subjects. 
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AUTONOMIC NEUROPATHY 
Diabetes is a major cause of autonomic nervous system 
dysfunction.   Autonomic dysfunction is common in patients with 
longstanding diabetes increasing age, poor glycaemic status and presence 
of risk factor related to cardiovascular system.  
It is one of the least understood and recognized complication of 
diabetes and has a very significant impact on quality of life and survival 
in individual who suffer with diabetes. 2 The disorders of metabolism in 
diabetes lead to a widespread and diffuse damage of small and large 
vessels, peripheral nerves and autonomic nerves.  
Involvement of ANS can damage cardiovascular, neurovascular , 
gastrointestinal and genitor-urinary systems and also impair certain 
metabolic functions like glucose counter-regulations. Autonomic 
neuropathy sets in gradually and it also progresses slowly. 
The prevalence of DAN will depend on the population which is 
studied and also the amount of tests for detection of autonomic function 
that are employed.  
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 In EURODIAB study, autonomic neuropathy prevalence was 
defined as presence of at least two abnormal CAN function tests. 
Diabetic autonomic neuropathy (DAN) is often associated with 
diabetic predominantly sensory neuropathy. It is frequently under 
diagnosed on a clinical basis. The severity of autonomic dysfunction 
ranges from asymptomatic to severe disability. 
 Common manifestations are pupillary size and reduction of light 
responses, episodic nocturnal diarrhea, constipation and gastric atony, 
orthostatic hypotension, dizziness, resting tachycardia, cardiac 
arrhythmia, and silent myocardial infarction. Genitourinary system 
dysfunction presents with bladder atonia, distention, recurrent infection, 
and impotence.17 
DAN is seen frequently in T1DM, and the incidence seems to 
increase with increasing age and longer duration of renal disease. 
Furthermore, patients suffering with DAN have a much increased risk of 
development of renal infections and unexplained cardiorespiratory arrest, 
with a higher mortality rate.  
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ORGANISATION OF ANS 
The ANS organisation and physiological control relies on its 
division into sympathetic and parasympathetic nervous system. Fight and 
flight is an important physiological response which is mediated by 
sympathetic stimulation and is manifest by increased heart rate , 
increased BP, energy store mobilisation and alertness. 
Epinephrine, nor-epinephrine and dopamine are the major 
neurotransmitters which mediate the cellular responses by some 
interaction with special G- protein coupled adrenergic receptors namely 
α1 ,α2& β1 ,β2 ,β3 and dopaminergic receptors namely D1 ,D2&D3. On 
the contrary, parasympathetic stimulation usually produces effects which 
are opposite to effects produced by stimulation of sympathetic nervous 
system .eg: decreased heart rate , decrease in cardiac contractility and 
increase of digestive function.  
Acetylcholine which is the major neurotransmitter in this system 
interacts with its muscaranic receptors which are G protein couples 
namely M 1-M5 and also with nicotinc receptors i.e  neuronal І – Ш 
,muscle type ІV. 
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Parasympathetic neurons are situated in brain stem medulla and 
also in the sacral region of one’s spinal cord. Sympathetic neurons reside 
in the thoracolumbar spinal cord. 
 Cranial nerves and also spinal nerves are helpful in projecting the 
pre synaptic myelinated axons to synapses located with in ganglia and 
from here the post synaptic unmyelinated fibres arise, which reach the 
innervated organ.  
Although these two systems apparently have opposite actions, a 
well coordinated firing by both is necessary. Physiological functions of 
ANS have been depicted in the following figure. 
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FUNCTIONS OF ANS 
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CLINICAL MANIFESTATIONS OF AUTONOMIC NEUROPATHY 
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CARDIOVASCULAR AUTONOMIC NEUROPATHY 
Where there is damage of autonomic fibres which innervate heart 
and its blood vessels, it causes certain abnormalities not only of heart rate 
control but also vascular dynamics. Technological advances in the past 
decade have made it possible to identify autonomic dysfunction in early 
stages with the help of objective standardised measures. This allows 
intervention earlier, when there is still a possibility to reverse the 
condition. CAN causes in some postural hypotension. There can also be 
peripheral blood flow alteration and cases of sudden death. 
POSTURAL HYPOTENSION 
A decrease in systolic BP more than 20 mm of Hg when patient 
gets up from sitting posture is the parameter for diagnosing postural 
hypotension. Treatment with TCA or diuretics therapy may exacerbate 
postural hypotension. Patients complaint of dizziness on standing but 
some patients have no symptoms. Postural hypotension is associated with 
increased mortality rate.19 
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TREATMENT  
 Better glycaemic control by use of insulin or OHA’s 
 Slow change of posture and avoidance of sudden postural change.  
 Use of Fludrocortisone in resistant cases in dose of  0.1 mg which 
can be gradually increased to maximal daily dose of 0.5 mg with 
renal function monitoring.  
 Support stockings   
 Midodrine 
 Octreotide 
ALTERATION IN PERIPHERAL BLOOD FLOW 
Arterio- venous shunting in patients with autonomic neuropathy, 
causes prominence of veins in already neuropathic leg. Due to 
sympathetic denervation the venous oxygen tension, skin blood flow, and 
capillary pressure are increased. If there is no peripheral vascular disease 
it will be a warm foot.  It is an important factor that causes osteopenia 
which leads to development of Charcot neuro-arthropathy. 
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CAN FUNCTION TESTS 
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AUTONOMIC GASTROPARESIS 
Vagal denervation usually of stomach may be the cause. 
Autonomic neuropathy causes decrease in oesophageal motility leading to 
dysphagia, heart burn and gastroparesis. The reduction in gastric 
emptying causes bloating, early satiety, vomiting and swings between 
hypoglycaemia and hyperglycaemia.  
Diagnosis is essentially clinical. Sometimes there is succusion 
splash. Investigations like barium swallow or gastroscopy can be helpful 
sometimes. Patients present with recurrent vomiting which causes 
dehydration, weight loss and frequent fluctuation in blood glucose.  
TREATMENT 
• Control of blood glucose fluctuations 
• Metoclopramide and domperidone  
• Drugs for gastric motility → Erythromycin  
• Gastrostomy tube feeding 
• Total parentral nutition 
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AUTONOMIC DIARRHOEA 
It is an uncommon presentation and is rarely severe. This 
complication is caused by autonomic denervation which leads to 
abnormal gut motility, causing bacterial overgrowth and 
malabsorption.ther is troublesome diarrhoea which is more at night and 
there are stages of remissions and recurrences.  
Faecal incontinence may set in. Constipation can also at times 
alternate with episodes of diarrhoea. Treatment is essentially 
conventional. 
ABNORMAL SWEATING 
It is the commonest symptom of DAN, it usually affect the face 
precipitated by food intake (Gustatory sweating).Glycopyrrolate can be 
used for topical application to treat gustatory sweating.  
Reduced sweating in feet causes dry feet leading to fissuring and 
sometimes infection. Nocturnal sweating not related to hypoglycaemia 
can be another presentation. 
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NEUROPATHIC BLADDER  
It is attributable to sacral nerve pathology. Usually patients are 
asymptomatic but may present with symptoms like hesistency and 
increased urinary frequency. Urinary retention or overflow incontinence 
can also be seen.   
These patients are prone to urinary tract infections.  Ultrasound 
screening, cystometrography, and intravenous urography are required for 
diagnosis.  Treatment manoeuvres include frequent bladder emptying 
either by supra-pubic pressure or they can be taught intermittent self-
catheterization.  Treatment is by neostigmine, pyridostigmine. 
ERECTILE DYSFUNCTION 
Autonomic neuropathy contributes to diabetic erectile dysfunction, 
as does vascular disease.  If no contraindication sildenafil can be used, or 
vacuum pumps or  vaso-active drugs such as papaverine (with or without 
phentolamine) or drosvaglandin E can be used.  Surgery is required, when 
large vessel is a significant contributor. 
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INVESTIGATION OF NEUROPATHY 
CLINICAL MEASURES 
• Assessment of signs and symptoms  
• Careful neurologic examination  
• In asymptomatic patients - horizontal graphic rating scale or a 
modification of the mcgill pain questionnaire   
QUANTITATIVE SENSORY TESTING 
 Vibration perception using  hand-held biothesiometer 
 Pressure sensation testing by Ten gram  semmes-weinstein 
monofilament 
 Tactile two-point discrimination  
 Thermal testing  
ELECTROPHYSIOLOGY 
This is not only the most sensitive and reliable test for peripheral 
nerve function but also is a reproducible test which correlates well with 
nerve biopsy results. Abnormalities are not found specific to diabetes.  
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MORPHOLOGIC ASSESSMENT 
Due to its invasive nature, difficulties in interpretation and 
problems with reproducibility, sural nerve biopsy for diagnosis of 
peripheral diabetic neuropathy is now obselete. 
ACUTE AXONAL POLYNEUROPATHY 
These syndromes are not common and are characterized by a 
sudden onset of pain affecting the feet and legs in a symmetrical manner.  
Two clinical syndromes have been identified 
Painful polyneuropathy associated with poor glycaemic status and 
acute painful polyneuropathy associated with rapid improvement in 
glycaemic status though they are unrelated to other complications of 
chronic diabetes. 
RAPIDLY REVERSIBLE HYPERGLYCEMIC NEUROPATHY 
Rapidly reversible nerve conduction abnormalities can often be 
seen in recently diagnosed diabetics or chronic diabetics with transiently 
poorly controlled diabetes and often associated with transient symptoms. 
There are usually no structural abnormalities.  
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Improvement in glycaemic status leads to complete recovery. 
Ellenburg coined the term ‘neuropathic cachexia’, characterised by 
marked weight loss, severe pain typically of burning quality and 
persistent sometimes associated with contact pain (allodynia).  
The rapid onset, the severity and the nocturnal exacerbation of 
symptoms often lead to depression. Motor signs are classically absent and 
ankle jerks are lost in few.   
NCS usually normal or maybe abnormal sometimes. Temperature 
discrimination threshold often reduced in patients. Complete resolution 
occurs within a year, and weight gain is usual with improvement in 
glycaemic control using exogenous insulin. 
RAPID GLYCAEMIC CONTROL RELATED ACUTE PAINFUL 
NEUROPATHY {‘INSULIN NEURITIS’} 
This occurs with rapid improvement in glycaemic status either with 
use of insulin or OHA’s.  It is characterised by burning pain, paraesthesia 
and allodynia, often with nocturnal exacerbation and depression. There is 
no associated weight loss. Loss of sensation may be mild or absent. There 
are no motor signs.  NCS are normal but there is reduced exercise-
induced increment of conduction velocity.  
 
 
                                                                                                             48 
 
 
 
Symptoms completely resolve within a year. Under anaerobic 
conditions the hypoxic nerves use glucose. Once the glucose in blood is 
normalized, glucose is no longer available for nutrition, consequently, the 
nerves undergo axonal degeneration. Normalization of blood glucose 
slowly with insulin improves the symptoms. 
PROXIMAL MOTOR NEUROPATHY (AMYOTROPHY) 
Diabetic proximal motor neuropathy can be symmetric or 
asymmetric. Lower limbs are more frequently involved. The term 
"diabetic amyotrophy" is commonly used for this form of neuropathy. 
The presentation is unique. 
In 1961, Garland coined the term "diabetic amyotrophy"7. The term 
diabetic proximal motor symmetric or asymmetric neuropathy has been 
proposed recently for this entity. Incidence of diabetic amyotrophy (DA) 
is around 1.1% in T2DM and 0.3% in T1DM. Males in fifth and sixth 
decade are predominantly affected.   
Proximal leg muscles are involved first, with symptoms like thigh 
pain, which is deep, achy, and at times jabbing. The pain is worse at 
night. The unilateral form is painful, and the bilateral form is less painful. 
Sensory symptoms such as paresthesias are unusual. Muscle weakness 
follows pain and weakness is first seen in quadriceps, glutei, iliopsoas, 
 
 
                                                                                                             49 
 
 
 
hamstrings, and adductors. Weakness may remain unilateral or bilateral 
and muscle atrophy may develop later.  
There are no fasciculations. Symmetric onset of DA is associated 
with generalized distal sensory motor polyneuropathy, less pain, slower 
progression, less weight loss, and frequently occurs in T1DM. Bowel and 
bladder function are spared. Knee jerks are absent.  
Electrophysiologic findings show slowing of motor and sensory 
nerves distally. Prolongation of femoral nerve motor latency and 
decreasing amplitude of compound muscle action potential may be 
present. Needle EMG shows a neurogenic pattern in the affected muscles.  
Muscle biopsy shows neurogenic features.  
Patients with DA improve within 6 to 12 months after controlling 
hyperglycemia but recovery is often incomplete. Pain resolves first and 
relapse occurs in 20% of cases. Root micro-infarction, degeneration of 
anterior horn cells, motor roots, or lumbosacral plexus are the common 
etiopathogenesis.  Nerve biopsy studies show vasculitic infiltrate.   
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MONONEUROPATHIES 
Isolated peripheral nerve lesions are present in diabetic patients, 
particularly in older individuals with T2DM.  Mononeuropathies are 
acute in onset and associated with pain in peripheral nerves like peroneal, 
median, or ulnar, and occurs at sites of entrapment or external 
compression .  
Cranial nerves particularly III and VI are most commonly affected. 
The exclusion of intracranial pathology, particularly malignancy or 
aneurysms, before making diagnosis of a diabetic cranial 
mononeuropathy is a must.   
Mononeuropathies gradually improve without any specific 
treatment, but surgical decompression may be required in certain 
entrapment neuropathies. 
DIABETIC MONONEUROPATHY MULTIPLEX 
Mononeuropathy multiplex has an abrupt onset, with pain, 
paresthesias, and motor weakness. Motor axons are predominantly 
affected. The diagnosis is based on two or more nerves involved at 
different time intervals and locations. Electrophysiologic studies are 
consistent with axonal neuropathy.  
 
 
                                                                                                             51 
 
 
 
DIABETIC CRANIAL NEUROPATHY 
The third cranial nerve palsy is the most common diabetic 
mononeuropathy. Patients present with orbital pain, drooping of eyelid or 
frontal headache.  On examination, partial ptosis and ophthalmoplegia is 
seen with pupillary  sparing .  Complete recovery usually occurs within 
three months, which sugests vascular aetiology.  
Pupillary response is spared because parasympathetic nerve fibers, 
which run at the periphery of the third nerve, are not affected because the 
ischemia affects the central portion of the nerve. 
  Exclusion of other causes of third cranial nerve palsy like 
aneurysm or tumour with the help of computerized tomographic or 
magnetic resonance imaging is important.  Paralysis of sixth and seventh 
cranial nerve, are comparatively less common in diabetics. 
TRUNCAL NEUROPATHY 
Predominatly affects the elderly. Diabetic truncal radiculopathies 
present with sudden pain which is suggestive of vascular cause. 
Distribution of pain is in the region of lower thorax or abdomen.  The 
pain is mostly asymmetrical. 
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Exclusion of other condition which may lead to nerve root 
compression is important.  Diagnosis can be difficult in those with 
abdominal pain and some patients may undergone unnecessary 
investigations like barium enema or colonoscopy. patients may land up 
with  laparotomy. Careful history taking and through clinical examination 
is key to diagnosis.   
Patient can be reassured strongly as complete recovery is usual 
within a year, although occasionally symptoms can be persistent for 
years.Diabetic thoracolumbar or thoracoabdominal neuropathy / 
radiculopathy affects older diabetics (>50 years).  
It is more common in T2DM and most patients give a history of 
significant weight loss. The syndrome was first described by Longstreth 
and colleagues in four diabetic patients who were evaluated extensively 
for abdominal pain. The onset of symptoms is chest and/or abdominal 
pain, more intense at night. Pain may radiate to the thigh or back and 
rarely to the neck.  
The skin over the chest or abdominal wall becomes sensitive to the 
touch. Unless the diagnosis is made early, most patients are subjected to 
extensive, expensive, and at times invasive procedures to rule out an 
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underlying carcinoma because of their age and unexplained pain with 
weight loss.  
The pain is intermittent and usually unilateral, although it may 
progress bilaterally. The pain is usually in the region of thoracolumbar 
roots. Sensory deficits usually have a dermatomal distribution. 
Involvement of the lumbar root may present with abdominal wall muscle 
weakness and herniation.  
Thoracolumbar neuropathy can present at the initial onset of 
diabetes. The diagnosis is based on a history of diabetes, weight loss, and 
the clinical features.  
Electrophysiologic studies often reveal evidence of generalized 
polyneuropathy. Needle EMG of the thoracic, lumbar, or abdominal wall 
muscles may show denervation changes.  
Controlling the glycemic state and improvement of the nutritional 
condition of the patient are the mainstays of treatment. Antidepressant or 
antiepileptic drugs may be used for pain control. Remission may occur 
within 6 to 12 months.  
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ENTRAPMENT NEUROPATHIES 
Pressure (entrapment) neuropathies affecting the median and ulnar 
nerve are more common in the diabetic population than in the general 
population.  Median nerve entrapment (carpal tunnel syndrome) cause 
pain and even paraesthesiae in hands. This can radiate to forearm, and is 
more marked at night.  
Examination reveals a reduction of sensation in the median 
territory of the hand (lateral 3½ fingers) and muscle wasting in the region 
of thenar eminence.  Diagnosis of carpel tunnel syndrome can be 
confirmed by median NCS.  
Surgical decompression is the treatment of choice. Patients usually 
respond well to surgical decompression but occasionally painful 
symptoms may relapse.Ulnar nerve entrapment at the ulnar groove in the 
elbow can also cause wasting of dorsal interossia, especially first. 
Ulnar electrophysiological studies can isolate the site of lesion and 
help confirm the diagnosis.  Other nerves that are vulnerable to 
entrapment are the lateral popliteal nerve which results in foot drop, the 
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radial nerve which can result in wrist drop and the lateral cutaneous nerve 
of the thigh causing meralgiaparaesthetica.  
The occurance of carpal tunnel syndrome in diabetes is estimated 
to be 23.3%.  Electrophysiologic evidence of carpal tunnel syndrome in 
asymptomatic patients is about 27%.  Ulnar nerve entrapment at the 
elbow is more frequent. The diagnosis of entrapment neuropathy is 
confirmed by electrophysiologic testing. 
TREATMENT 
Management of Painful Diabetic Neuropathy 
 Exclusion of other causes of neuropathy 
 Psychological support for the patient 
 Non pharmacological treatments: for example, bed cradle, opsite 
for contact pain 
 Pharmacological treatments 
o Optimization of glycaemic control  
o Tricyclic antidepressants (imipramine or amitriptyline, 25-
150 mg taken at night; SSRIs if tricyclics are not well 
tolerated) 
o Anticonvulsants (gabapentin 900-3600 mg/day in divided 
doses, carbamazepine 200-800 mg/day) 
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o Tramadol (50-400 mg/day) 
o Capsaicin cream (0.075%) 
o IV lignocaine (0.5 mg/kg given over 30 min) 
o Aldose reductase inhibitors 
o α lipoic acid 
 Electric spinal cord stimulation if no response or if there are 
unacceptable side effects to pharmacotherapy 
 Transcutaneous electric nerve stimulation (TENS) 
CANS ANALYSER 
CANS analyser is an important tool to measure and diagnose 
autonomic dysfunction using R-R intervals of ECG and automatic BP 
measurements. The test procedure are guided by computer software and 
both cardiac sympathetic and parasympathetic autonomic functions are 
analysed. 
 
 
                                                                                                             57 
 
 
 
 
CLINICAL TESTING OF AUTONOMIC NEUROPATHY : 
Quantitative tests to assess autonomic function show less 
advancement than those used to assess the functions and deficits of motor 
and sensory nerves.10  
It was believed that autonomic neuropathy had little if any 
contribution and correlation to peripheral neuropathies which commonly 
affect diabetic patients. More than forty years back the following five 
simple and noninvasive tests to assess cardiovascular reflex were 
proposed. 
 
The above mentioned tests have been utilized successfully in a 
number of studies and for assessment of patients with features suggestive 
of autonomic dysfunction.  
It is mandatory to rule out end organ damage before subjecting the 
patient to these tests. They are valid, specific and significant time tested 
procedures to diagnose autonomic neuropathy noninvasively. 
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Co-morbid illness, use of drugs like anti-histamines, anti-tussives, 
antidepressants, diuretics and aspirin should not be there. Patients are 
advised to abstain from smoking and drinking coffee at least one hour 
before the test. 
Heart rate response to deep breathing 
Heart rate varies with respiration and this is determined by the 
parasympathetic system. To assess this response, patient is instructed to 
lie down quietly and is told to take slow deep breaths at a rate of six per 
minute. ECG monitors maximum and minimum heart rate.  
Heart rate response to standing 
The patient is asked to get up from lying posture and heart rate to 
this response is assessed. After standing, the heart rate normally increases 
and is maximum at about fifteenth beat after attaining vertical posture. 
The heart rate then starts falling and is minimum at about thirtieth beat. 
Hence R-R variation between fifteen and thirtieth beats ate assessed.23 
Valsalva maneuver 
Originally used as a method to expel pus from middle ear which is 
done by blowing and straining with closed nose and mouth. The patient 
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first takes a deep breath and then expires forcibly against a closed glottis 
for a period of ten to twenty seconds.  
Alternatively to test for autonomic function, patient needs to blow 
into a sphygmomanometer such that a pressure level of at least forty mms 
is maintained for thirty seconds. Valsalva maneuver is associated with a 
short duration increase of intraocular pressure as well as intra cranial 
pressure. This leads to a risk of hemorrhage within the eye and 
dislocation of lens. The risk is somehow known to be low because similar 
increase in pressure occur in day to day activities also.  
There are four phases described as normal response to valsalva 
maneuver.  
Phase 1: at the beginning of straining, there is a short duration of 
increase in intrathoracic pressure which causes increased BP and 
decreased heart rate. This happens because the elevated pressure 
compresses the aorta thereby propelling blood into peripheral circulation.  
Phase 2: This is the straining phase where there is decrease in BP 
initially which later is recovered. There is associated reflex tachycardia, 
stroke volume reduces because of decrease in venous return. 
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Phase 3:  cessation of straining in this phase causes an increase in 
venous return. There is an abrupt but transient fall in BP and increased 
heart rate. 
Phase 4: this is the overshoot phase where the event returns to pre-
valsalva state after about 6 to 8 beats. There is an initial overshoot of BP 
wide pulse pressure and also reflex bradycardia. ECG tracing during the 
maneuver are taken to calculate ratio between longest and shortest R-R 
interval. Normal is 1.6.  
Systolic blood pressure response to standing 
Otherwise known as postural hypotension and has been discussed 
earlier. 
Diastolic BP response to sustained handgrip 
A hand grip dynamometer is used to detect increase of systolic and 
diastolic BP and chang in heart rate. The patient is supposed to squeeze 
the dynamometer to its maximum followed by a slow release to keep it at 
a level of at least 30 % of maximum for 120 to 180 seconds. Normally 
after the hand grip is released, there will be an increase of diastolic BP to 
more than 16 mm of Hg. Abnormal response is less than 10 mm of Hg 
increase in BP. 
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We look for reduced variability (less of a change in heart rate), a 
sign that the patient’s heart response, as provided by the body’s 
autonomic control center, is not adequate. At least two tests must be 
performed in order for the test to be conclusive. Sometimes one test result 
may be abnormal, but the second test result turns out normal.  
This is because some heart rate variability tests are more sensitive 
to earlier autonomic nervous system dysfunction than others. This is also 
due to the fact that test results are based on a combination of activities 
within the body, which are influenced differently in each patient. As a 
general rule, the more tests that result in abnormal results, the more 
severe the end organ damage is to the autonomic nervous system. 
 Perhaps the most important things we can do for our patients with 
diabetes are to make them aware of autonomic neuropathy, to let them 
know whether they have it, and to help them keep blood sugar levels in 
an acceptable range.  
Doing so not only helps reduce the risk of heart disease, but also 
lowers the risk of diabetic eye, kidney and nerve disease, each of which 
patients  want to avoid.  
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Diabetic autonomic neuropathy has been called a "silent killer," 
because so few patients realize that they suffer from it, and yet its effects 
can be so lethal. With a brief, 15-minute test that we can administer in the 
office, and some relatively modest interventions, we can help many 
patients live longer, healthier lives. 
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MATERIAL AND METHODS 
SETTING 
This study was conducted at the Institute of Diabetology, Rajiv 
Gandhi Government General Hospital and Madras Medical College. 
ETHICAL COMMITTEE APPROVAL 
Obtained. 
STUDY DURATION 
This study was conducted over a period of four months. 
STUDY POPULATION 
Patients attending Diabetology outpatient department at Institute of 
Diabetology. 
SAMPLE SIZE 
Hundred and two T2DM patients who attended outpatient 
department. 
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TYPE OF STUDY 
Observational study. 
INCLUSION CRITERION 
 Patients diagnosed with Type 2 Diabetes Mellitus of any duration. 
 Patients equal to or more than 30 years of age and less than 70 
years  
EXCLUSION CRITERIA 
 Type 1 Diabetes Mellitus 
 Gestational Diabetes Mellitus 
 Secondary Diabetes Mellitus 
 Patients on pacemakers 
 Patients on anti-arrythmic drugs 
 Patients with self reported neurological disease. 
 Patients with known cardiac disease  
 Patients less than 30 years and more than 70 years 
ANALYSIS PLAN 
 Chi square test 
 SPSS version 17.0 
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DATA COLLECTION AND METHODS 
 
Informed consent was obtained from each patient or the relative. 
Patients had their history taken according to a Questionnaire and 
were subjected to clinical examination. 
Patients were subjected to investigations like 
Renal function tests 
Plasma glucose  
HbA1c  
Urine microalbuminuria 
Cardiac autonomic neuropathy testing 
Biothesiometry 
Fundus examination of the eye 
All data was entered in proforma and master chart prepared for 
data analysis. 
Data was analysed using XlStat 
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Renal function tests: Serum creatinine was done by Jaffe’s method 
Plasma glucose was done by glucose oxidation method  
HbA1c by High pressure liquid chromatography 
Urine PCR: urine proteins determined by turbidimetric method 
using 3% sulphosalicylic acid and creatinine by Jaffe’s method.  
All the investigation were done at lab of Institute of Diabetology 
by well trained technicians  
Cardiac autonomic neuropathy testing using CANS analyser with 
software. 
Biothesiometry by Biothesiometer with software 
Fundus examination of the eye by ophthalmologist at Regional 
Institute of  Ophthalmology, Egmore. 
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OBSERVATION AND RESULTS 
AGE DISTRIBUTION 
AGE 
GROUP(years) 
MALES FEMALES 
30-40 4 12 
41-50 13 13 
51-60 20 23 
61 – 70 12 5 
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AGE AND CANS 
   Cans Dysfunction Total P value 
    Normal Early Definite 
Modera
te   
Age in 
years 
30-40 Count 5 7 3 1 16   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.013* 
    % within 
Age in 
years 
31.3% 43.8% 18.8% 6.3% 100.0% 
    % within 
Cans 
Dysfuncti
on 
25.0% 19.4% 8.3% 10.0% 15.7% 
  41-50 Count 8 12 6 0 26 
    % within 
Age in 
years 
30.8% 46.2% 23.1% .0% 100.0% 
    % within 
Cans 
Dysfuncti
on 
40.0% 33.3% 16.7% .0% 25.5% 
  51-60 Count 5 13 21 4 43 
    % within 
Age in 
years 
11.6% 30.2% 48.8% 9.3% 100.0% 
    % within 
Cans 
Dysfuncti
on 
25.0% 36.1% 58.3% 40.0% 42.2% 
  61-70 Count 2 4 6 5 17 
    % within 
Age in 
years 
11.8% 23.5% 35.3% 29.4% 100.0% 
    % within 
Cans 
Dysfuncti
on 
10.0% 11.1% 16.7% 50.0% 16.7% 
Total Count 20 36 36 10 102 
  % within 
Age in 
years 
19.6% 35.3% 35.3% 9.8% 100.0% 
  % within 
Cans 
Dysfuncti
on 
100.0% 100.0% 100.0% 100.0% 100.0% 
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SEX DISTRIBUTION 
SEX NO. OF CASES PERCENTAGES 
MALE 49 48 
FEMALE 53 52 
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SEX DISTRIBUTION AND CANS 
   Cans Dysfunction Total 
P value 
    Normal Early Definite 
Moderat
e   
 
Sex Male Count 12 18 13 6 49  
    % within 
Sex 24.5% 36.7% 26.5% 12.2% 100.0% 
 
    % within 
Cans 
Dysfunct
ion 
60.0% 50.0% 36.1% 60.0% 48.0% 
 
  Female Count 8 18 23 4 53  
    % within 
Sex 15.1% 34.0% 43.4% 7.5% 100.0% 
0.173 
    % within 
Cans 
Dysfunct
ion 
40.0% 50.0% 63.9% 40.0% 52.0% 
 
Total Count 20 36 36 10 102  
  % within 
Sex 19.6% 35.3% 35.3% 9.8% 100.0% 
 
  % within 
Cans 
Dysfunct
ion 
100.0% 100.0% 100.0% 100.0% 100.0% 
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DURATION OF T2DM (IN YEARS) 
 
<1 1 TO 5 6  TO 10 11 TO 15 >15 
MALES  12 15 11 6 5 
FEMALES 12 15 15 7 4 
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DURATION OF T2DM AND CANS 
   Cans Dysfunction Total P value 
    Normal Early Definite 
Modera
te   
 
Duration in 
years 
< 1 Count 5 10 7 1 23  
    % within 
Duration in 
years 
21.7% 43.5% 30.4% 4.3% 100.0% 
 
    % within 
Cans 
Dysfunctio
n 
25.0% 27.8% 19.4% 10.0% 22.5% 
 
  1-5 Count 6 11 12 2 31  
    % within 
Duration in 
years 
19.4% 35.5% 38.7% 6.5% 100.0% 
 
    % within 
Cans 
Dysfunctio
n 
30.0% 30.6% 33.3% 20.0% 30.4% 
 
  6-10 Count 4 10 9 3 26  
    % within 
Duration in 
years 
15.4% 38.5% 34.6% 11.5% 100.0% 
 
    % within 
Cans 
Dysfunctio
n 
20.0% 27.8% 25.0% 30.0% 25.5% 
0.772 
  11-15 Count 4 3 3 3 13  
    % within 
Duration in 
years 
30.8% 23.1% 23.1% 23.1% 100.0% 
 
    % within 
Cans 
Dysfunctio
n 
20.0% 8.3% 8.3% 30.0% 12.7% 
 
  > 15 Count 1 2 5 1 9  
    % within 
Duration in 
years 
11.1% 22.2% 55.6% 11.1% 100.0% 
 
    % within 
Cans 
Dysfunctio
n 
5.0% 5.6% 13.9% 10.0% 8.8% 
 
Total Count 20 36 36 10 102  
  % within 
Duration in 
years 
19.6% 35.3% 35.3% 9.8% 100.0% 
 
  % within 
Cans 
Dysfunctio
n 
100.0% 100.0% 100.0% 100.0% 100.0% 
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NORMAL CANS 
 
30-40 41-50 51-60 61-70 
 
Males Females Males Females Males Females Males Females 
<1 1 2 1 0 0 1 1 0 
1 TO 5 1 1 1 0 1 0 1 0 
6 TO 10 0 0 1 1 0 2 0 0 
11 TO 
15 0 0 3 1 0 0 0 0 
>15 0 0 0 0 1 0 0 0 
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EARLY CANS 
 
30-40 41-50 51-60 61-70 
 
Males Females Males Females Males Females Males Females 
<1 0 2 1 2 3 2 1 0 
1 TO 5 0 3 3 1 3 0 1 0 
6 TO 10 0 1 1 3 2 2 0 1 
11 TO 15 1 0 0 0 0 2 0 0 
>15 0 0 1 0 0 0 1 0 
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DEFINITE CANS 
 
30-40 41-50 51-60 61-70 
 
Males Females Males Females Males Females Males Females 
<1 0 1 0 2 2 0 1 0 
1 TO 5 0 1 1 2 2 5 0 1 
6 TO 10 0 1 0 1 2 3 2 0 
11 TO 15 0 0 0 0 0 2 1 0 
>15 0 0 0 0 1 3 1 0 
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MODERATE CANS 
 
30-40 41-50 51-60 61-70 
 
Males Females Males Females Males Females Males Females 
<1 1 0 0 0 0 0 0 0 
1 TO 5 0 0 0 0 0 1 1 0 
6 TO 10 0 0 0 0 2 0 1 0 
11 TO 15 0 0 0 0 1 0 0 2 
>15 0 0 0 0 0 0 0 1 
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CANS AND GLYCAEMIC STATUS 
 
HbA1c NORMAL EARLY DEFINITE MODERATE 
≤7 5 10 9 3 
7.1 -8 7 10 11 1 
8.1-9 2 6 5 3 
9.1-10 3 3 4 1 
>10 3 7 7 2 
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HbA1c AND CANS 
   Cans Dysfunction Total P value 
    Normal Early Definite 
Moderat
e   
 
HBA1c <= 7 Count 5 10 9 3 27  
    % within 
HBA1c 18.5% 37.0% 33.3% 11.1% 100.0% 
 
    % within 
Cans 
Dysfuncti
on 
25.0% 27.8% 25.0% 30.0% 26.5% 
 
  7.1-8 Count 7 10 11 1 29  
    % within 
HBA1c 24.1% 34.5% 37.9% 3.4% 100.0% 
 
    % within 
Cans 
Dysfuncti
on 
35.0% 27.8% 30.6% 10.0% 28.4% 
 
  8.1-9 Count 2 6 5 3 16  
    % within 
HBA1c 12.5% 37.5% 31.3% 18.8% 100.0% 
 
    % within 
Cans 
Dysfuncti
on 
10.0% 16.7% 13.9% 30.0% 15.7% 
0.827 
  9.1-10 Count 3 3 4 1 11  
    % within 
HBA1c 27.3% 27.3% 36.4% 9.1% 100.0% 
 
    % within 
Cans 
Dysfuncti
on 
15.0% 8.3% 11.1% 10.0% 10.8% 
 
  > 10 Count 3 7 7 2 19  
    % within 
HBA1c 15.8% 36.8% 36.8% 10.5% 100.0% 
 
    % within 
Cans 
Dysfuncti
on 
15.0% 19.4% 19.4% 20.0% 18.6% 
 
Total Count 20 36 36 10 102  
  % within 
HBA1c 19.6% 35.3% 35.3% 9.8% 100.0% 
 
  % within 
Cans 
Dysfuncti
on 
100.0% 100.0% 100.0% 100.0% 100.0% 
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CANS AND NEPHROPATHY (PCR) 
PCR NORMAL EARLY DEFINITE MODERATE 
 
MALES FEMALES MALES FEMALES MALES FEMALES MALES FEMALES 
≤ 0.2 10 8 15 16 10 19 5 2 
>0.2 2 0 3 2 3 4 1 2 
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PCR AND CANS 
   Cans Dysfunction Total  
    Normal Early Definite 
Moderat
e   
 
UPCR Normal Count 18 31 29 7 85  
    % within 
UPCR 21.2% 36.5% 34.1% 8.2% 100.0% 
 
    % within 
Cans 
Dysfuncti
on 
90.0% 86.1% 80.6% 70.0% 83.3% 
 
  Abnorma
l 
Count 2 5 7 3 17 0.301 
    % within 
UPCR 11.8% 29.4% 41.2% 17.6% 100.0% 
 
    % within 
Cans 
Dysfuncti
on 
10.0% 13.9% 19.4% 30.0% 16.7% 
 
Total Count 20 36 36 10 102  
  % within 
UPCR 19.6% 35.3% 35.3% 9.8% 100.0% 
 
  % within 
Cans 
Dysfuncti
on 
100.0% 100.0% 100.0% 100.0% 100.0% 
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CANS AND NEPHROPATHY (SERUM CREATININE) 
SERUM NORMAL EARLY DEFINITE MODERATE 
CR MALES FEMALES MALES FEMALES MALES FEMALES MALES FEMALES 
≤ 1.2 10 8 15 17 10 19 6 2 
> 1.2 2 0 3 1 3 4 0 2 
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SERUM CREATININE AND CANS 
   Cans Dysfunction Total P value 
    Normal Early Definite 
Modera
te   
 
Creatinine Normal Count 18 32 30 10 90  
    % within 
Creatinine 20.0% 35.6% 33.3% 11.1% 100.0% 
 
    % within 
Cans 
Dysfunctio
n 
90.0% 88.9% 83.3% 100.0% 88.2% 
 
  Abnormal Count 2 4 6 0 12 0.524 
    % within 
Creatinine 16.7% 33.3% 50.0% .0% 100.0% 
 
    % within 
Cans 
Dysfunctio
n 
10.0% 11.1% 16.7% .0% 11.8% 
 
Total Count 20 36 36 10 102  
  % within 
Creatinine 19.6% 35.3% 35.3% 9.8% 100.0% 
 
  % within 
Cans 
Dysfunctio
n 
100.0% 100.0% 100.0% 100.0% 100.0% 
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CANS AND NEUROPATHY 
NEUROPATHY NORMAL EARLY DEFINITE MODERATE 
 
MALES FEMALES MALES FEMALES MALES FEMALES MALES FEMALES 
ABSENT 11 6 9 13 2 15 3 1 
PRESENT 1 2 9 5 11 8 3 3 
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NEUROPATHY AND CANS 
   Cans Dysfunction Total P value 
    Normal Early Definite 
Moderat
e   
 
Bioth Present Count 17 22 17 4 60  
    % within 
Bioth 28.3% 36.7% 28.3% 6.7% 100.0% 
 
    % within 
Cans 
Dysfunct
ion 
85.0% 61.1% 47.2% 40.0% 58.8% 
 
  Absent Count 3 14 19 6 42  
    % within 
Bioth 7.1% 33.3% 45.2% 14.3% 100.0% 
0.006 
    % within 
Cans 
Dysfunct
ion 
15.0% 38.9% 52.8% 60.0% 41.2% 
 
Total Count 20 36 36 10 102  
  % within 
Bioth 19.6% 35.3% 35.3% 9.8% 100.0% 
 
  % within 
Cans 
Dysfunct
ion 
100.0% 100.0% 100.0% 100.0% 100.0% 
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CANS AND RETINOPATHY 
RETINOPATHY NORMAL EARLY DEFINITE MODERATE 
 
MALES FEMALES MALES FEMALES MALES FEMALES MALES FEMALES 
ABSENT 10 7 13 16 9 15 3 1 
PRESENT 2 1 5 2 4 8 3 3 
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RETINOPATHY AND CANS 
   Cans Dysfunction Total P value 
    Normal Early Definite 
Moderat
e   
 
Fundus Present Count 17 29 24 4 74  
    % within 
Fundus 23.0% 39.2% 32.4% 5.4% 100.0% 
 
    % within 
Cans 
Dysfuncti
on 
85.0% 80.6% 66.7% 40.0% 72.5% 
 
  Absent Count 3 7 12 6 28  
    % within 
Fundus 10.7% 25.0% 42.9% 21.4% 100.0% 
0.034 
    % within 
Cans 
Dysfuncti
on 
15.0% 19.4% 33.3% 60.0% 27.5% 
 
Total Count 20 36 36 10 102  
  % within 
Fundus 19.6% 35.3% 35.3% 9.8% 100.0% 
 
  % within 
Cans 
Dysfuncti
on 
100.0% 100.0% 100.0% 100.0% 100.0% 
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RESULTS 
The present study comprised of 102 subjects of which 49 were 
males and 52 were females. A total of 82 (80.39%) were found to have 
CANS dysfunction of varying degrees. 75.7% males and 84.61% females 
were detected with CANS dysfunction. 
Early CANS dysfunction was detected in 18 of 49 males (36.73%) 
and 17 of 52 females (32.69%). Definite CANS dysfunction was seen in 
13 males (26.53%) and 21females (40.38%). Moderate CANS was 
detected in 6 males (12.2 %) and 4 females (7.69%).  
When we compared age of patients with CANS function we found 
that in the age group of 31 to 40 years of 4 males 50% had normal CANS 
and 50% had CANS dysfunction. Of 12 females, 3 had (25%) normal 
CANS and 9(75%) had CANS dysfunction. 
In 41to 50 years age group, of 13 males 6(46.15%) had no CANS 
dysfunction and 7(53.86%) had CANS dysfunction. Among the 13 
females 2(15.38%) had normal CANS and 11(84.62%) had CANS 
dysfunction. 
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In 51 to 60 years age group, of the 20 males 2(10%) had normal 
CANS and 18(90%) had CANS dysfunction. Of 23 females 3(13.04%) 
has normal CANS and 20(86.96%) had CANS dysfunction. 
In 61 to 70 years age group, of 12 males 2(16.66%) had normal 
CANS and 10(83.33%) had CANS dysfunction. All 5 females (100%) in 
this group had varying degrees of CANS dysfunction. 
On comparing duration of diabetes with CANS dysfunction there 
were a total of 24 patients with less than 1 year of diabetes. Among these 
6(25%) had normal CANS and 18(75%) had CANS dysfunction. 
In the 30 subjects with duration of diabetes between 1 to 5 years 
5(16.66%) had normal CANS and 25(83.33%) had CANS dysfunction. 
In 6 to 10 years duration cohort we had 26 patients of which 
4(15.38%) had normal CANS and 22(84.62%) had CANS dysfunction. 
In 11 to 15 years diabetes duration group of a total of 13 patients, 
4(30.76%) had normal CANS and 9(69.24%) had CANS dysfunction. 
In the 9 patients with diabetes more than 15 years, 1(11.11%) had 
normal CANS whereas 8(88.89%) had CANS dysfunction.   
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A total of 27 patients had HbA1c of less than 7%. In this group 
with good glycaemic control, only 5 (18.51%) had normal CANS 
whereas 10 (37.03%) had early CANS, 9 (33.3%) had definite and 3 
(11.11%) had moderate CANS dysfunction. 
Among the 29 patients with HbA1c between 7.1 to 8 %, 7(24.13%) 
had normal CANS but 10 (34.48%) had early, 11(37.93%) definite and 1 
(3.44%) had moderate CANS dysfunction. 
In the cohort with 8.1 to 9 HbA1c there were 16 patients. Of these 
2(12.2 %) had normal CANS, 6(36.5%) had early, 5(31.25%) had definite 
and 3(18.75%) had moderate CANS dysfunction.  
In 9.1 to 10 HbA1c group of 11 patients 3(27.2%) had normal 
CANS, 3 (27.2%) early, 4 (36.36%) definite and 1 (9.09%) moderate 
CANS dysfunction. 
19 patients had HbA1c > 10 %, of which 3 (15.78%) had normal 
CANS, 7(36.8%) early, 7(36.8%) definite and 2 (10.52%) moderate 
CANS dysfunction. 
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Diabetic nephropathy was detected in 17 patients who were 
enrolled in this study. Among the patients with nephropathy 15(88.23%) 
had CANS dysfunction. 85 patients were without nephropathy and CANS 
dysfunction was present in 67(78.8%) 
60 patients had no neuropathy detected by biothesiometry. Of these 
17(28.3%) had normal CANS and 43 (17.6%) had varied degrees of 
CANS dysfunction. A total of 42 patients were diagnosed with peripheral 
neuropathy of this 3 (7.1%) had normal CANS whereas 39(92.85%) had 
varying degrees of CANS dysfunction.  
74 patients had no retinopathy. Among them 17 (22.9%) had 
normal CANS function whereas 57(77.02%) had some degree of CANS 
dysfunction. A total of 28 patients were diagnosed with different stages of 
retinopathy and in this cohort there were 3 (10.7%) with normal CANS 
and 25(89.28%) with varying degrees of CANS dysfunction.  
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CONCEPT OF P VALUE 
 
 If the P value is  0.000 to  0.010 then significant at 1 level (highly 
significant ) 
 
 If the P value is 0.011 to 0.050 then significant at 5 level 
(significant ) 
 
 If the P value is 0.051 to 1.000 then not significant at 5 level (not 
significant) 
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DISCUSSION 
In this present study the overall prevalence of CAN in the South 
Indian T2DM population was found to be 80.39%. Of this 34.31% had 
early CANS 33.33% had definite CANS and 9.80% had moderate CANS 
dysfunction. During history taking and physical examination all these 
patients who were included in the study were asymptomatic in relation to 
cardiac autonomic neuropathy. 
Research done by Andrzej S.Krolewski who correlated CAN with 
retinopathy in type 1 DM found a strong correlation of CAN with diabetic 
retinopathy but diabetic nephropathy correlated weakly. Another study by 
Vincenza Spallone showed relationship between autonomic neuropathy, 
24 hours BP profile and nephropathy in normotensive T1DM patients and 
DAN was significantly associated to increased urinary albumen 
excretion.  
Basu et al from eastern India studied 50 patients with T2DM and 
their study revealed 54% prevalence and it was strongly associated with 
retinopathy and microalbuminuria. 
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Study by Elizabeth et al showed definite CANS dysfunction in 
23% and early CANS dysfunction in 33%. No significant difference was 
found for gender and HbA1c but CAN was more common with older age, 
higher BP, nephropathy, neuropathy and retinopathy. 
EURODIAB study found age, poor gylcaemic status, high systolic 
BP, neuropathy and retinopathy to be significant risk factors for CAN 
dysfunction. 
Our study is unique as we have not only estimated the prevalence 
of cardiac autonomic neuropathy in T2DM population but also correlated 
it with diabetic neuropathy, nephropathy, retinopathy, HbA1c, age of 
patients, gender, and duration of diabetes. 
In our study we found that CAN was not significantly associated 
with duration of diabetes, HbA1c and nephropathy. 
There was almost equal distribution of the disease among both 
sexes. There was a significant association of CAN with increasing age, 
neuropathy, and retinopathy.  
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LIMITATIONS OF STUDY 
 
 The cohort was not large enough to represent the whole 
population. 
 
 A control group was not included in this study 
 
 Nephropathy was diagnosed by urine PCR method. 
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CONCLUSIONS 
 Cardiac autonomic neuropathy dysfunction appears much before 
patient manifest signs and symptoms of this disease. 
 
 Hence CANS testing should be mandatory and started early to 
insist better metabolic control. 
 
 As the problem is associated with other micro vascular 
complication, further deterioration should be prevented. 
 
 Age has a significant association with cardiac autonomic 
neuropathy, hence elderly diabetic patients need regular CANS 
evaluation. 
 
 CAN dysfunction is almost equal in prevalence among both the 
sexes. 
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PROFORMA 
PREVALANCE OF CARDIAC AUTONOMIC NEUROPATHY IN 
TYPE 2 DIABETES MELLITUS AND ITS CORRELATION WITH 
OTHER MICROVASCULAR COMPLICATIONS 
Name : Patient ID No: 
Age/Sex :      Contact No: 
Occupation: 
COMPLAINTS 
☐ Postural giddiness    ☐ Numbness of hands and 
feet 
☐ Gustatory sweating     ☐ Pins and needles 
sensation  
☐ Palpitation     ☐ Facial puffiness 
☐ Bowel and bladder disturbances  ☐ Decreased urine output 
☐ Sexual dysfunction    ☐ Peripheral edema 
☐ Cotton wool sensation    ☐ Blurring of vision  
 
PAST HISTORY 
☐ HT ☐ CAD 
☐ Kidney disease ☐ STROKE/TIA 
☐ Other Neurological disease 
 
PERSONAL HISTORY  
☐ Smoking 
☐ Alcohol intake 
 
GENERAL EXAMINATION 
BP: Lying: 
BP: Standing:                                        
PULSE: 
WEIGHT:                                       
HEIGHT:                                      
BMI:  
SKIN:    
 
SYSTEMIC EXAMINATION: 
CVS: 
RS: 
P/A: 
CNS: 
INVESTIGATIONS 
Blood Urea:    mg/dl 
Serum Creatinine:   mg/dl 
Plasma glucose-   
Fasting:    mg/dl 
Postprandial:   mg/dl 
HbA1c:    % 
Urine PCR: 
 
CAN analysis 
 
Biothesiometry 
 
Ophthalmic Fundus examination 
 
ECG 
 
 
  
PATIENT CONSENT FORM 
Study Title : Prevalance of cardiac autonomic neuropathy in Type 2 
Diabetes Mellitus and its correlation with other 
microvascular complications 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Name :  
Age/Sex :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to 
me in my own language  
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected.  
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study 
and any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties 
or published, unless as required under the law. I agree not to restrict the use 
of any data or results that arise from this study.  
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms.  
I hereby consent to participate in this study.  
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological and biochemical tests.  
 
 
 
Signature/thumb impression    Signature of Investigator  
Patient’s Name and Address:                      Study Investigator’s Name: 
 
S.No AGE SEX Du COM PG HBA1c UPCR UREA Cr BIOTH FUNDUS PARASYMPATHETIC SYMPATHETIC CANS DYSFUNCTION
1 61 F 10Y 119 6.4 0.03 18 1 MOD NPDR RHR GR II ST GR I GR 0 EARLY CANS 
2 44 F 6Y HT 138 6.4 0.02 21 0.9 ML N NORMAL NORMAL NORMAL
3 45 M 4Y 236 12.3 0.02 16 0.7 N N STANDING GR II GR 0 EARLY CANS
4 47 M 3Y PSY ILL 270 12.6 0.02 22 1.2 N N STANDING GR II GR 0 EARLY CANS
5 52 M 9 M 93 6.4 0.03 24 1.1 N N STANDING GR II GR 0 EARLY CANS
6 38 F 7Y HT 248 10.4 0.03 20 0.8 ML N STANDING GR II GR 0 EARLY CANS
7 68 M 30Y HT 182 8.3 0.44 44 1.4 MOD NPDR STANDING GR II GR 0 EARLY CANS
8 57 M 3Y HT 146 6.7 0.02 20 1.1 N N STANDING GR II SHG GR I EARLY CANS
9 55 F 3Y 207 10.3 0.03 18 0.9 N N DB GR II ST GR II SHG GR I DEFINITE CANS
10 33 F 1Y HYP 231 8.8 0.02 34 1.2 N N GR 0 GR 0 NORMAL
11 66 M N D 207 10.4 0.32 52 1.5 N N  GR 0 NORMAL
12 40 F N D PSY ILL 178 6.9 0.03 22 1 N N DB GR I ST GR II SHG GR II DEFINITE CANS
13 59 F 7Y 291 9.2 0.02 18 1 N N NORMAL GR 0 NORMAL
14 62 M 3Y HT 72 4.9 1.4 52 3 ML NPDR STANDING GR II SHG GR II EARLY CANS
15 60 M 3Y 199 11.2 0.05 18 1 N N GR 0 GR 0 NORMAL
16 56 M 1Y 146 8.4 0.02 20 1.1 N N STANDING GR II GR 0 EARLY CANS
17 51 F 6Y HT CKD 114 6 0.64 45 2.1 ML N DB GRII ST GRII SHG GR I DEFINITE CANS
18 63 F 2Y 173 8.1 0.02 19 1 MOD N STANDING GR II SHG GR II DEFINITE CANS
19 67 M 6Y 118 7 0.03 20 1.1 ML N STANDING GR II SHG GR II DEFINITE CANS
20 56 F 11Y 76 6.2 0.04 20 0.9 N NPDR NORMAL SHG GR II EARLY CANS
21 55 F N D 116 10.3 0.02 20 0.9 N N STANDING GR I SHG GR II EARLY CANS
22 54 M 10Y 136 9.9 0.7 20 1.1 SEV NPDR DB GR II ST GR II SHG GR I DEFINITE CANS
23 53 M 14Y HT 164 7.5 0.02 24 0.9 MOD NPDR DB GRII RHR GRII ST GRII SHG GR II MODERATE CANS
24 56 M N D 171 8 0.3 68 1.7 MOD NPDR DB GRI RHR GR II ST GRII SHG GR I EARLY CANS
25 54 F 6Y HT 155 7.2 0.05 23 1.1 N N NORMAL GR 0 NORMAL
26 70 M 7Y HT 180 7.4 0.02 28 1.2 ML N DB GR II ST GR II GR 0 DEFINITE CANS
27 49 F 6Y HT Ca Cx 170 5.7 0.03 18 0.9 SEV N DB GR II ST GR II SHG GR 0 DEFINITE CANS
28 49 M 4Y 206 8.2 0.03 18 1.2 N N STANDING GR II SHG GR I EARLY CANS
29 54 F 7Y HT 88 5.4 0.42 40 1.8 ML N STANDING GR II SHG GR I EARLY CANS
30 35 F 4Y 144 9.4 0.03 18 1 N N STANDING GR II SHG GR II EARLY CANS
31 40 M 12Y 165 10.1 0.03 21 1 MOD N STANDING GR II SHG GR II EARLY CANS
32 43 F 14Y 130 7.8 0.03 18 0.8 MOD NPDR NORMAL GR 0 NORMAL
33 52 M 8Y HT 139 9.8 0.03 26 1.1 ML N STANDING GR II SHG GR I EARLY CANS
34 55 F 3Y HT 92 5.8 0.02 20 0.9 ML NPDR DB GR II ST GR II SHG GR II MODERATE CANS
35 67 F 12Y HT 220 11.1 0.28 33 1.3 N N DB GR II ST GR II SHG GR II MODERATE CANS
36 68 M 18Y 89 6.5 0.03 18 1 ML NPDR STANDING GR II SHG GR II DEFINITE CANS
37 32 M 3 M 102 5.7 0.03 18 1 N N RESTING GR II SHG GR II MODERATE CANS
38 45 F 3 M 130 8.2 0.03 25 1.1 N N RESTING  HR II SHG GR I EARLY CANS
39 64 M N D 146 7.9 0.02 20 1.1 ML N STANDING GR II SHG GR II DEFINITE CANS
40 61 M 10Y 106 5.7 0.13 18 1.2 ML N DB GR II ST GR II SHG GR II MODERATE CANS
41 56 F 8Y HT 198 9 0.03 30 0.9 ML N STANDING GR II SHG GR I EARLY CANS
42 49 F 8Y 81 6.8 0.02 23 1 N N STANDING GR II SHG GR I EARLY CANS
43 58 F 7Y 258 14 0.1 26 1.2 ML NPDR DB GRII ST GR I SHG GR I DEFINITE CANS
44 38 F 2Y 238 9 0.02 22 0.9 N N STANDING GR II SHG GR I EARLY CANS
45 57 F 2Y 119 7.1 0.03 20 1 N N STANDING GR II SHG GR II DEFINITE CANS
46 60 F 16Y 181 8.3 0.04 28 1.1 SEV NPDR STANDING GR II SHG GR II DEFINITE CANS
47 59 M 17Y 352 6.4 0.03 18 1 MOD NPDR NORMAL GR 0 NORMAL
48 55 F 4Y 147 8.2 0.5 44 1.4 N NPDR STANDING GR II SHG GR II DEFINITE CANS
49 57 F 12Y 207 10.4 0.03 25 1.2 N NPDR STANDING GR II SHG GR II DEFINITE CANS
50 58 F 4Y HT 96 7 0.03 18 1 ML N STANDING GR II SHG GR II DEFINITE CANS
51 56 M 4Y 145 6.8 0.02 26 1 N N NORMAL SHG GR II EARLY CANS
52 55 F 5 M 153 7.4 0.04 17 0.7 N N RESTING HR GR II SHG GR II DEFINITE CANS
53 45 F 6Y 182 7.9 0.03 23 1.1 N N DB GR I SHG GR II EARLY CANS
54 37 F N D 201 7.4 0.04 18 1.1 N N NORMAL SHG GR II EARLY CANS
55 47 F 5Y 76 6.9 0.09 22 1.1 ML N NORMAL SHG GR II EARLY CANS
56 55 F 2Y 436 10 0.04 22 1.2 N N STANDING GR II SHG GR II DEFINITE CANS
57 43 M 1Y 123 8.3 0.03 21 0.8 N N DEEP BREATHING GR II SHG GR II DEFINITE CANS
58 45 M N D 184 7.8 0.05 23 0.9 N N NORMAL SHG GR II EARLY CANS
59 44 M N D 208 8.2 0.03 23 1.1 N N NORMAL GR 0 NORMAL
60 53 F N D 130 5.4 0.02 34 1 N N NORMAL GR 0 NORMAL
61 47 M 20Y 148 12.2 0.06 30 1.1 ML NPDR STANDING GR I SHG GR I EARLY CANS
62 37 M 1 M 110 7.2 0.04 23 1 N N NORMAL GR 0 NORMAL
63 52 M 7Y HT 230 8.4 0.04 19 1.1 ML NPDR DB GR II RHR GR II ST GRII SHG GR II MODERATE CANS
64 57 M 10Y HT 121 6.2 0.34 49 1.6 MOD NPDR STANDING GR II SHG GR II DEFINITE CANS
65 60 F 13Y 185 10.9 0.02 26 1 N N NORMAL SHG GR II EARLY CANS
66 47 F N D 182 8.9 0.03 23 1.1 N N STANDING GR II SHG GR II DEFINITE CANS
67 40 F N D 153 7.5 0.04 17 0.9 N N STANDING GR I SHG GR II EARLY CANS
68 58 M 2Y 304 10.3 1.12 57 2.4 ML NPDR STANDING GR II SHG GR II DEFINITE CANS
69 54 F 8Y HT HYP 149 12.2 0.6 48 2 N NPDR STANDING GR II SHG GR II DEFINITE CANS
70 59 M N D HT 385 14 0.03 26 1.2 MOD N STANDING GR II SHG GR II DEFINITE CANS
71 50 F N D 145 8 0.02 26 1 N N STANDING GR II SHG GR II DEFINITE CANS
72 38 F 8Y 130 7.4 0.02 34 1 N N STANDING GR II SHG GR II DEFINITE CANS
73 68 M 2Y 184 10.2 0.54 42 1.9 N NPDR NORMAL NORMAL NORMAL
74 40 F 1Y 174 9.7 0.04 21 1.1 N N STANDING GR II SHG GR II DEFINITE CANS
75 51 M 7Y HT 138 6.5 0.03 21 1.1 ML N STANDING GR I SHG GR II EARLY CANS
76 50 F 1Y HT 127 7.4 0.04 18 0.6 MOD N STANDING GR II SHG GR II DEFINITE CANS
77 50 F 7Y HT 209 8 0.04 22 1 N N NORMAL SHG GR II EARLY CANS
78 50 F 3 M HT 148 7.8 0.6 28 0.8 N N STANDING GR I SHG GR II EARLY CANS
79 30 F 2 M 207 9.8 0.06 20 0.8 N N NORMAL GR 0 NORMAL
80 51 M 4Y 85 7 0.04 38 1.3 MOD N DEEP BREATHING GR II SHG GR II DEFINITE CANS
81 60 F 12 Y HT 229 13.3 0.1 27 1.1 N NPDR DB GR II RHR GR II SHG GR 0 DEFINITE CANS
82 52 F 16Y 184 9.9 0.01 18 1 N NPDR STANDING GR II SHG GR II DEFINITE CANS
83 63 M 1Y 149 8.7 0.04 19 1.1 N N DB GR II ST GR II SHG GR II MODERATE CANS
84 32 F 2Y HT HYP 232 9.4 0.04 24 1.2 N N STANDING GR II GR 0 EARLY CANS
85 55 M N D 132 7.2 0.03 27 1.2 N N NORMAL SHG GR II EARLY CANS
86 57 M N D HT 192 8 0.04 22 0.8 N N STANDING GR II SHG GR II DEFINITE CANS
87 40 F 3Y 89 5.4 0.02 18 0.6 N N NORMAL GR 0 NORMAL
88 45 F 3Y 131 6.8 0.02 23 1 N N STANDING GR II SHG GR II DEFINITE CANS
89 43 M 6Y 159 7.2 0.04 29 1.2 ML N STANDING GR II GR 0 EARLY CANS
90 70 M N D 249 8 0.03 22 1.2 ML PDR STANDING GR I SHG GR II EARLY CANS
91 60 F 16Y 207 7.6 0.26 42 1.4 SEV NPDR STANDING GR II SHG GR II DEFINITE CANS
92 63 M 11Y HT 134 8 0.06 20 1.1 ML N STANDING GR II SHG GR II DEFINITE CANS
93 65 F 12Y HT HYP 168 9.2 0.08 24 1.2 MOD NPDR DB GR II ST GR II SHG GR II MODERATE CANS
94 50 M 13Y 188 9.9 0.12 27 1.2 N N NORMAL GR 0 NORMAL
95 68 F 17Y 269 12.8 0.4 42 1.3 ML NPDR DB GR II ST GR II SHG GR II MODERATE CANS
96 32 M 3Y 127 7.1 0.02 18 0.7 N N NORMAL GR 0 NORMAL
97 41 M 12Y 141 7.6 0.03 20 1 N N NORMAL GR 0 NORMAL
98 55 M 7Y 172 8.8 0.3 36 1.2 N NPDR DB GR II ST GR II SHG GR II MODERATE CANS
99 60 M 18Y HT 144 7.8 0.06 28 1.1 MOD N STANDING GR II SHG GR II DEFINITE CANS
100 50 M 11Y HT 131 7.4 0.04 24 1 N N NORMAL GR 0 NORMAL
101 49 M 4Y 122 6.4 0.03 18 0.8 N N NORMAL GR 0 NORMAL
102 42 M 6Y 174 7.8 0.04 20 0.9 N N NORMAL GR 0 NORMAL
  
  
  
 
 
